Page 3«..2345..1020..»

Category : Nanomedicine

Nanobiotix 2019 Q4 and Annual Revenues – Business Wire

PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Regulatory News:

NANOBIOTIX (Paris:NANO) (Euronext : NANO ISIN : FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited annual revenues for Q4 and the unaudited revenues for the year ended December 31, 2019.

2019 Revenues

In K

Twelve months Ended

December 31st, 2019

Twelve months Ended

December 31st, 2018

Revenues

68

105

Of which licenses

-

-

Of which services

68

99

Other sales

-

6

Revenue for Q4 2019

In K

Q4 2019

Q3 2019

Q2 2019

Q1 2019

Revenues

20

11

32

5

Of which licenses

-

-

-

-

Of which services

20

11

32

5

Activity and results

Nanobiotixs revenue for the fourth quarter amounted to approximatively 20k.

Most of the revenues generated by the Company during this period result from the recharge of costs related to our license and collaboration agreement with PharmaEngine.

Overall, Nanobiotixs annual revenue in 2019 amounted to approximatively 68k.

The amount of cash and cash equivalent as of December 31st, 2019 amounted to 35 094k. This amount does not include the research tax credit related to 2018, normally expected in Q4 which was received in February 2020.

In November 2019, Nanobiotix announced promising results from a pre-clinical immuno-oncology study of NBTXR3 at the 2019 Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In the study, conducted at The University of Texas MD Anderson Cancer Center, researchers studied NBTXR3 activated by radiation therapy in combination with anti-PD-1 treatment in immunocompetent mice. Combination treatment that included NBTXR3 and anti-PD-1 increased local control of the irradiated tumor, generated a marked abscopal effect, decreased the number of spontaneous lung metastases, and significantly increased survival when compared to other treatments in the study, including anti-PD-1 combined with radiation therapy alone. The results indicated that the combination treatment has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.

The study also included an in vivo RadScopal model in which a second tumor received a low dose of radiation while the first tumor received a full dose. In this model, researchers evaluated NBTXR3 activated by radiation therapy combined with anti-PD-1 and anti-CTLA-4 treatment. In the study, combination treatment triggered better local control, along with significant increases in abscopal effect and survival, when compared to all other tested combinations. Several complete responses were observed in the second tumor of the group that received the NBTXR3 combination, while none were observed in the other groups. Nanobiotix believes these results could pave the way for the use of NBTXR3 to improve treatment outcomes for immunooncology patients, including checkpoint inhibitor non-responders.

On December 16th 2019, Nanobiotix received the French 2019 Prix Galien award for Most Innovative MedTech. This award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.

2020 Financial agenda

Nanobiotix plans to announce its financial and operating results as follows:

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. The Company also possesses an affiliate, Curadigm, located in Paris, France and Cambridge, MA in the U.S.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

See the original post here:
Nanobiotix 2019 Q4 and Annual Revenues - Business Wire

Recommendation and review posted by Alexandra Lee Anderson

2020-2025 Global and Regional Nanomedicine Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report -…

The global Nanomedicine market report by HNY Research offers users a detailed overview of the market and all the main factors affecting the market. The study on global Nanomedicine market, offers profound understandings about the Nanomedicine market covering all the essential aspects like revenue growth, supply chain, sales, key players and regions. There is a target set in market that every marketing strategy has to reach. This report on Nanomedicine focusses on different categories that define this market with a systematic approach that addresses the consumer base, researchers and market experts like the stakeholders. It also gives a clear perspective towards the competition and demand and supply chain.

Request a sample of this report @ https://www.orbisresearch.com/contacts/request-sample/4361506

Manufacturer Detail

By Market Players:Combimatrix, Ablynx, Abraxis Bioscience, Celgene, Mallinckrodt, Arrowhead Research, GE Healthcare, Merck, Pfizer, Nanosphere, Epeius Biotechnologies, Cytimmune Sciences, Nanospectra Biosciences

By Application

By TypeQuantum dots, Nanoparticles, Nanoshells, Nanotubes, Nanodevices

The Nanomedicine market report also offers some presentations and illustrations about the market that comprises pie charts, graphs, and charts which presents the percentage of the various strategies implemented by the service providers in the global Nanomedicine market. This report on Nanomedicine has been very well drafted to benefit anyone studying it. There are different marketing strategies that every marketer looks up to in order to ace the competition in the Global market. Some of the primary marketing strategies that is needed for every business to be successful are Passion, Focus, Watching the Data, Communicating the value To Your Customers, Your Understanding of Your Target Market. Every market research report follows a robust methodology to define its market value. By doing so, the Nanomedicine research study by HNY Research offers collection of information and analysis for each facet of the Nanomedicine market such as technology, regional markets, applications, and types.

Browse the complete report @ https://www.orbisresearch.com/reports/index/2020-2025-global-and-regional-nanomedicine-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

This study can benefit investors and business owners in many ways. It studies the business models, strategies, growth, innovations and every information about manufacturers that can help make business predictions and fetch good results. Making right business decisions is an undeniable measure that needs to be taken for market growth. Every market has a set of manufacturers, vendors and consumers that define that market and their every move and achievements becomes a subject of studying for market researchers and other stakeholders. One of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Nanomedicine report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. Another important aspect of every market research report by HNY Research is the study of the key players or manufacturers driving the market forward. The process helps to analyze the opponent thoroughly.

Make an enquiry of this report @ https://www.orbisresearch.com/contacts/enquiry-before-buying/4361506

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

See more here:
2020-2025 Global and Regional Nanomedicine Industry Production, Sales and Consumption Status and Prospects Professional Market Research Report -...

Recommendation and review posted by Alexandra Lee Anderson

Phase 2 Remyelination Trial Yields ‘Intriguing’ Interim Results – Medscape

WEST PALM BEACH, FL Among patients with relapsing multiple sclerosis (MS) and visual impairment who received a potential remyelinating treatment or placebo for as long as 36 weeks, median low-contrast letter acuity improved in the population overall, according to an interim, blinded analysis.

Exploratory outcome measures of cognition, gait, and upper extremity function also improved.

The results do not mean that the treatment works. "We know that placebo works. I'm not here to tell you that the drug works. I'm just here to tell you that we have intriguing data," said Robert Glanzman, MD, chief medical officer of Clene Nanomedicine, the developer of the drug.

The patients in the interim analysis represent about 25% of the target study population of 150 patients, Glanzman said. The phase 2, double-blind, randomized, controlled trial, VISIONARY-MS, is assessing the efficacy and safety of CNM-Au8, a suspension of clean-surfaced gold nanocrystals that may support intracellular biologic processes. Patients are randomly assigned to receive low-dose CNM-Au8, high-dose CNM-Au8, or placebo taken orally once daily.

Neuroprotective or remyelinating agents are an unmet need in MS, Glanzman said. VISIONARY-MS has enrolled patients at centers in Australia and recently expanded the trial sites in North America. He presented the interim data during a joint symposium of the North American Imaging in MS Cooperative and the International Multiple Sclerosis Visual System Consortium at the meeting held by the Americas Committee for Treatment and Research in Multiple Sclerosis.

VISIONARY-MS is enrolling participants with chronic optic neuropathy, defined as visual impairment with no episodes of acute optic neuritis within the 6 months prior to enrollment, and nonactive disease, defined as no MS relapses within the prior 3 months. Patients may take concomitant immunomodulatory disease-modifying MS therapies during the trial.

The primary endpoint is improvement in low-contrast letter acuity (LCLA) from baseline to week 24. Secondary endpoints are change in amplitude and latency of multifocal visual evoked potential. Other functional measures are exploratory endpoints. Participants remain in the trial through week 48 or until the last participant completes week 24.

Among the first 34 enrolled participants, median LCLA improved by about five letters, Glanzman said.

Patients also had median improvement on other subscales of the modified Multiple Sclerosis Functional Composite (MSFC) that assess cognition (Symbol Digit Modalities Test), upper extremity function (9-Hole Peg Test), and gait (Timed 25-foot Walk).

CNM-Au8 has been well tolerated, and no serious adverse events related to the study drug have been reported. The most frequent adverse events include headache, upper respiratory infection, and sore throat. Full unblinded results are anticipated in 2021.

About 60% of patients in the interim analysis were female, and the mean Expanded Disability Status Scale score was less than 2, Glanzman said.

"These data add to the growing body of clinical evidence demonstrating that CNM-Au8, a suspension of catalytic, clean-surfaced, faceted gold nanocrystals, has the unique ability to improve remyelination and provide axonal neuroprotection," Glanzman said in a news release. "The consistent median improvements observed across the MSFC functional domains in the population of participants in VISIONARY-MS are exciting."

At previous meetings, research has described data from studies that have provided evidence of efficacy in animal models of MS. An overview of the preclinical studies "Nanocatalytic activity of clean-surfaced, faceted nanocrystalline gold enhances remyelination in animal models of multiple sclerosis" was published recently in Scientific Reports. Preclinical studies in animal models of diseases other than MS also have shown evidence of neuroprotection, Glanzman said.

"We are studying the visual system in order to interrogate the nervous system as a whole," he said. "The visual system is by far the most sensitive to change." The design of VISIONARY-MS was informed by a trial of clemastine fumarate as a potential remyelinating agent in patients with chronic optic neuropathy, Glanzman added.

Glanzman is an employee of Clene Nanomedicine, and receives salary and stock options.

Source: 5th annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020. Abstract.

This story originally appeared on MDedge.com.

Read the original:
Phase 2 Remyelination Trial Yields 'Intriguing' Interim Results - Medscape

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine Market 2020: by Top Manufactures, Production, Consumption, Trade Statistics, Growth Analysis, Industry Share and Forecast to 2026 – Daily…

Nanomedicine Market Global Industry Report 2020 offer target audience with the fresh outlook on market and fill in the knowledge gaps with the help of processed information and opinions from industry experts. The information in the research report is well-processed and a report is accumulated by industry professionals and seasoned experts in the field to ensure of the quality of research.

Get a Sample Copy of this Report at https://www.orianresearch.com/request-sample/1035385

Development policies and plans are discussed as well as growth rate, manufacturing processes, economic growth are analyzed. This research report also states import/export data, industry supply and consumption figures as well as cost structure, price, industry revenue (Million USD) and gross margin by regions.

Nanomedicine Market Important Factors:

Global Nanomedicine Market: Regional Analysis:

The report offers in-depth assessment of the growth and other aspects of the Nanomedicine market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

For competitor segment, the report includes global key players of Nanomedicine Market as well as some small players. The information for each competitor includes:

Global Nanomedicine Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period 2020-2026

Inquire more or share questions if any before the purchase on this report @ https://www.orianresearch.com/enquiry-before-buying/1035385

Market segment by Type, the product can be split into

Market segment by Application, split into

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the Nanomedicine market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the Nanomedicine market better.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Get Full Copy of This Report @ https://www.orianresearch.com/checkout/1035385

In this study, the years considered to estimate the market size of Nanomedicine are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

Table of Contents Nanomedicine Market Research Report is:

1 Nanomedicine Market Report Overview

2 Global Nanomedicine Market Growth Trends

3 Nanomedicine Market Share by Key Players

4 Nanomedicine Market Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Nanomedicine Market Forecast 2020-2026

14 Analysts Viewpoints/Conclusions

15 Appendix

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Read the rest here:
Nanomedicine Market 2020: by Top Manufactures, Production, Consumption, Trade Statistics, Growth Analysis, Industry Share and Forecast to 2026 - Daily...

Recommendation and review posted by Alexandra Lee Anderson

MS News that Caught My Eye Last Week: Remyelination Research in… – Multiple Sclerosis News Today

In this column, Ill be highlighting some of the research presented at this years Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held last week in West Palm Beach, Florida.

Youll need to read to the end of this news story to get to the most interesting information. The researchers data indicate that human glial progenitor cells can be transplanted into areas of the central nervous systems of mice where myelin has been damaged, to remyelinate them. Its worth a long read to see how the researchers support their conclusions.

Transplanting humanglial progenitor cells (GPCs) brain cells able to generate myelin-producing cells effectively led to remyelination in the brains of adult mice with myelin disorders, a study found.

These results were presented atthe Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020, running Feb 2729 in Florida,by John Mariani, PhD, with the University of Rochester.

His presentation was titled Human Glial Progenitor Cells Effectively Remyelinate The Demyelinated Adult Brain.

Click here to read the full story.

***

Heres another early study about myelin. This one involves an agent thats designed to increase energy reserves within neurons and myelin-producing cells, or oligodendrocytes, while decreasing toxic metabolic byproducts. Its expected that the process will improve the survival and function of those neurons and support the ability of oligodendrocytes to create new myelin.

Clene Nanomedicine shared early results of the VISIONARY-MS trial, suggesting that CNM-Au8 an investigational remyelinating therapy leads to notable trends in better vision, as well as benefits in mobility and manual function in relapsing multiple sclerosis(MS) patientswith chronic vision problems.

These findings were presented during the Joint NAIMS-IMSVISUAL Symposium at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020, running Feb. 2729 in Florida, by Robert Glanzman, MD, Clenes chief medical officer.

Preclinical tests in mice demonstrated that CNM-Au8 stimulatesthe production of new myelin, and increases the number of myelin-wrapped nerve fibers in the brain and spinal cord, allowing animals to recover motor skills.

Click here to read the full story.

***

Id expect that worsening neurological function would result in depression, but Im surprised to read that it may also be the other way around that depression may cause neurological function to decline. These researchers found that individuals who began their study being depressed had a 20 percent or greater chance than others of having one or more of their neurological performance scores worsen a year later.

Multiple sclerosis (MS) patients with depression are more likely to have worsening neurological function compared with those who do not have the mood disorder, results from a real-world study show.

The findings were presented Feb. 27 by Jenny Feng, MD, in an oral presentation titled Depression In MS Is Associated With Worsening Neuroperformance, Relapses, And New Brain Lesions at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2020, taking place Feb. 27-29 in West Palm Beach, Florida.

Click here to read the full story.

***

The U.S. Food and Drug Administration is expected to decide by June whether to approve the disease-modifying therapy ofatumumab, while the European Medicines Agencys decision is expected sometime in 2021. Ofatumumab is a fully human monoclonal antibody that binds to the CD20 marker on certain B-cells, depleting those cells a process similar to the way Ocrevus (ocrelizumab) works.

Both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will review Novartis applications seeking regulatory approval of ofatumumab, aninvestigational B-cell therapy for the treatment of relapsing forms ofmultiple sclerosis(MS) in adults.

Novartis applications for ofatumumab which has the potential to become a first-choice treatment for relapsing MS patients, easily self-administered using an autoinjector pen were accepted by both the U.S. and EU regulatory agencies.

Click here to read the full story.

***

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to multiple sclerosis.

Ed Tobias is a retired broadcast journalist. Most of his 40+ year career was spent as a manager with the Associated Press in Washington, DC. Tobias was diagnosed with Multiple Sclerosis in 1980 but he continued to work, full-time, meeting interesting people and traveling to interesting places, until retiring at the end of 2012.

Excerpt from:
MS News that Caught My Eye Last Week: Remyelination Research in... - Multiple Sclerosis News Today

Recommendation and review posted by Alexandra Lee Anderson

Nanobiotix 2019 Q4 and Annual Revenues – BioSpace

NANOBIOTIX (Paris:NANO) (Euronext : NANO ISIN : FR0011341205 the Company), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited annual revenues for Q4 and the unaudited revenues for the year ended December 31, 2019.

2019 Revenues

In K

Twelve months Ended

December 31st, 2019

Twelve months Ended

December 31st, 2018

Revenues

68

105

Of which licenses

-

-

Of which services

68

99

Other sales

-

6

Revenue for Q4 2019

In K

Q4 2019

Q3 2019

Q2 2019

Q1 2019

Revenues

20

11

32

5

Of which licenses

-

-

-

-

Of which services

20

11

32

5

Activity and results

Nanobiotixs revenue for the fourth quarter amounted to approximatively 20k.

Most of the revenues generated by the Company during this period result from the recharge of costs related to our license and collaboration agreement with PharmaEngine.

Overall, Nanobiotixs annual revenue in 2019 amounted to approximatively 68k.

The amount of cash and cash equivalent as of December 31st, 2019 amounted to 35 094k. This amount does not include the research tax credit related to 2018, normally expected in Q4 which was received in February 2020.

In November 2019, Nanobiotix announced promising results from a pre-clinical immuno-oncology study of NBTXR3 at the 2019 Annual Meeting of the Society for Immunotherapy of Cancer (SITC). In the study, conducted at The University of Texas MD Anderson Cancer Center, researchers studied NBTXR3 activated by radiation therapy in combination with anti-PD-1 treatment in immunocompetent mice. Combination treatment that included NBTXR3 and anti-PD-1 increased local control of the irradiated tumor, generated a marked abscopal effect, decreased the number of spontaneous lung metastases, and significantly increased survival when compared to other treatments in the study, including anti-PD-1 combined with radiation therapy alone. The results indicated that the combination treatment has the potential to achieve an equivalent abscopal effect at a lower dose of radiation.

The study also included an in vivo RadScopal model in which a second tumor received a low dose of radiation while the first tumor received a full dose. In this model, researchers evaluated NBTXR3 activated by radiation therapy combined with anti-PD-1 and anti-CTLA-4 treatment. In the study, combination treatment triggered better local control, along with significant increases in abscopal effect and survival, when compared to all other tested combinations. Several complete responses were observed in the second tumor of the group that received the NBTXR3 combination, while none were observed in the other groups. Nanobiotix believes these results could pave the way for the use of NBTXR3 to improve treatment outcomes for immunooncology patients, including checkpoint inhibitor non-responders.

On December 16th 2019, Nanobiotix received the French 2019 Prix Galien award for Most Innovative MedTech. This award recognizes outstanding biomedical and medical technology product achievements that improve the human condition.

2020 Financial agenda

Nanobiotix plans to announce its financial and operating results as follows:

About NANOBIOTIX: http://www.nanobiotix.com

Incorporated in 2003, Nanobiotix is a leading, clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

The Nanobiotix philosophy is rooted in designing pioneering, physical-based approaches to bring highly effective and generalized solutions to address unmet medical needs and challenges.

Nanobiotixs first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Nanobiotixs Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Companys headquarters are in Paris, France with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany. The Company also possesses an affiliate, Curadigm, located in Paris, France and Cambridge, MA in the U.S.

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business, including its prospects and product candidate development. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the reference document of Nanobiotix registered with the French Financial Markets Authority (Autorit des Marchs Financiers) under number R.19-018 on April 30, 2019 (a copy of which is available on http://www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005446/en/

Go here to see the original:
Nanobiotix 2019 Q4 and Annual Revenues - BioSpace

Recommendation and review posted by Alexandra Lee Anderson

EthicaMeat: Committed to Constructing a "World in Which Anyone Who Wants to Eat Meat Can do so Without Killing an Animal" – vegconomist -…

Inigo Charola, CEO EthicaMeat

Ethicameat is the cultivated meat brand of Biotech Foods, a pioneering Spanish company that says it is driving a revolution in the global food market; natural slaughter-free animal meat. Ethicameat says it is addressing the high demand for animal-based protein and reducing the current impact of the production process on the environment through sustainable solutions.

We were pleased to speak with Iigo Charola, CEO of Biotech Foods about their brand EthicaMeat, the future of protein and the role in which cultured meat will play.

Who is the team behind Ethica Meat?The company comprises a diverse team of experts in biomedicine, specialising in tissue regeneration and nanomedicine, which covers process engineering and pharmacology and biotechnology, in combination with a deep understanding of the food market.

Mercedes Vila is our Co-Founder and CTO of Ethicameat. She has a PhD in Materials Physics from the Autonoma University of Madrid-CSIC, and more than 16 years of experience in the design and application of materials in biomedicine and the understanding of surface interactions between cells and materials. In 2010 she was awarded the LORAL-UNESCO For Women in Science Prize in recognition of her scientific career. In 2012 she was appointed Distinguished Researcher through the I3 Programme of the Spanish Ministry of Science and Technology and she has been awarded three times the Marie-Sklodowska Curie Action of the European Commission.

Since the beginning of her career Vila has worked on the possibilities offered by tissue engineering and nanomedicine in the field of regeneration and treatment of the human body. In 2017 Vila cofounded BioTech Foods, the company that produces Ethicameat, the cultivated meat brand of Biotech Foods.

Iigo Charola is CEO and Co-Founder of BioTech Foods. He has a degree in Business Administration from the University of Wales, a Masters in Marketing Management from the prestigious ESIC Business & Marketing School and an MBA from the University of Deusto, as well as numerous leadership programs in Business Administration. He has developed his career as business director in several industries, including food technology, for more than 20 years.

Why cultured meat, and why now?Factory farming meat production model is developed on an unsustainable scale for a depleted planet. Today, factory farming accounts for 25% of the land and water use on the planet and 15% of greenhouse gas emissions. Sustained development of this model is threatening the existing and long-term capacity of the Earths resources. We are therefore facing the challenge of an unsustainable model in the long-term.

Global demand for protein currently stands at 202 million tonnes a year. This includes all types of meat and fish. This demand is forecast to increase to 1000 million tonnes by 2050, according to the latest data from the Food and Agriculture Organization (FAO) of the United Nations. This means that it is essential to find a sustainable alternative that, combining the most advanced technology with environmental protection, meets future demand.

Cultivated meat production uses much fewer resources: 99% less land, 75% less water and 90% fewer greenhouse gas emissions than similar meat products.

What is your company mission and how do you hope to achieve it?The mission of BioTech Foods is to commit to the construction of a world in which anyone who wants to eat meat can do so without killing an animal. A world where animal welfare, food safety and innovation would be the values that drive our species out to a more sustainable planet.

What will your portfolio be and when will the products be available?BioTech Foods works on pork meat and have plans to expand to poultry after that. We are currently developing our product offering for the consumer. Biotech Foods is collaborating with meat processing companies to obtain the final format of Ethicameat products, that will be launched in a range of consumer products such as sausages, ham and nuggets. The selected species give us a huge variety of potential products. Ethicameat is currently in the production scaling and regulation stage, before starting with the commercialization.

Where will your products be on sale, in which markets?Biotech Foods is collaborating with meat processing companies to obtain the final format of Ethicameat products that will be launched initially in the EU and in the US after first market introduction.

Are you seeking partners? We are very proud of the fact that our company already has raised over 2.5 million euros and our plan is to reach our short-term goals. We think collaboration is key to bring this new products into the market, so we keep collaborations in all parts of the value chain and we expect to keep growing those collaborations.

What are your plans for 2020 and the next few years?We now have the technology developed and we are now in the scale up process to bring cultivated meat to industrial production.

In the long term, we want to become a consumer alternative to traditional meat, a means to a much more important goal: sustainability between meat consumption, respect for animal welfare and the environment.

How do you foresee the future of the meat industry and which part will cultivated meat play? Are people ready for it in 2020? There are different forecasts about how protein consumption is going to evolve. What all of them have in common is that they predict a decrease of consumption of factory farming meat and plant bases and cultivated meat to be a substantial part of the proteins we consume. Some reports estimate this trend will keep rising to 2040, when cultivated meat will have a 35% share of all protein consumption.

Both production methods will undoubtedly co-exist because the consumer will demand it, but there seems to be no doubt that the overall production model will benefit.

Related

Here is the original post:
EthicaMeat: Committed to Constructing a "World in Which Anyone Who Wants to Eat Meat Can do so Without Killing an Animal" - vegconomist -...

Recommendation and review posted by Alexandra Lee Anderson

Nano Therapy Market Projected to Show Strong Growth | Key Players: Parvus Therapeutics, Nanoprobes, Nanospectra Biosciences – The Market Journal

Latest Study on Industrial Growth ofGlobal Nano Therapy Market2019-2025. A detailed study accumulated to offerLatest insights about acute features of the Nano Therapy market. The report contains different market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary and SWOT analysis.

The Major Players Covered in this Report: Nanoprobes, Nanospectra Biosciences, Parvus Therapeutics, Smith And Nephew, Selecta Biosciences, Sirnaomics, Tarveda Therapeutics & Sirnaomics

Nano Therapy Market Study guarantees you to remain / stay advised higher than your competition. With Structured tables and figures examining the Nano Therapy, the research document provides you a leading product, submarkets, revenue size and forecast to 2025. Comparatively is also classifies emerging as well as leaders in the industry.

Click To get SAMPLE PDF (Including Full TOC, Table & Figures)

This study also covers company profiling, specifications and product picture, sales, market share and contact information of various regional, international and local vendors of Global Nano Therapy Market. The market opposition is frequently developing greater with the rise in scientific innovation and M&A activities in the industry. Additionally, many local and regional vendors are offering specific application products for varied end-users. The new merchant applicants in the market are finding it hard to compete with the international vendors based on reliability, quality and modernism in technology.

Nanotherapy is a branch of nanomedicine that involves using nanoparticles to deliver a drug to a given target location in the body so as to treat the disease through a process known as targeting.Much of the research in nanotherapy has been largely directed towards cancer therapy. One of the biggest issues with conventional methods is that as the drug product is distributed throughout the body, both healthy and unhealthy (cancerous cells) are affected, which in turn affects the effectiveness of cancer treatment. It is for this very reason that most cancer patients tend to be hesitant when it comes to chemotherapy. However, nanotherapy, which is also referred to as targeted therapy, offers to deliver the molecules to the affected cells in order to help treat the disease without causing other negative effects to the healthy cells.In 2017, the global Nano Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

Read Detailed Index of full Research Study at @ https://www.htfmarketreport.com/reports/1339056-global-nano-therapy-market

The titled segments and sub-section of the market are illuminated below:

In-depth analysis of Global Nano Therapy market segments by Types: , Nanomaterial And Biological Device, Nano Electronic Biosensor, Molecular Nanotechnology & Implantable Cardioverter-Defibrillators

In-depth analysis of Global Nano Therapy market segments by Applications: Cardiovascular Disease, Cancer Therapy, Diabetes Treatment & Rheumatoid Arthritis

Major Key Players of the Market: Nanoprobes, Nanospectra Biosciences, Parvus Therapeutics, Smith And Nephew, Selecta Biosciences, Sirnaomics, Tarveda Therapeutics & Sirnaomics

Regional Analysis for Global Nano Therapy Market:North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Furthermore, the years considered for the study are as follows:Historical year 2013-2017Base year 2018Forecast period** 2018 to 2023 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=1339056

Guidance of the Global Nano Therapy market report:

Detailed considerate of Nano Therapy market-particular drivers, Trends, constraints, Restraints, Opportunities and major micro markets. Comprehensive valuation of all prospects and threat in the Global Nano Therapy market. In depth study of industry strategies for growth of the Nano Therapy market-leading players. Nano Therapy market latest innovations and major procedures. Favorable dip inside Vigorous high-tech and market latest trends remarkable the Market. Conclusive study about the growth conspiracy of Nano Therapy market for forthcoming years.

What to Expect from this Report On Nano Therapy Market:

1. A comprehensive summary of several area distributions and the summary types of popular products in the Nano Therapy Market.2. You can fix up the growing databases for your industry when you have info on the cost of the production, cost of the products, and cost of the production for the next future years.3. Thorough Evaluation the break-in for new companies who want to enter the Nano Therapy Market.4. Exactly how do the most important companies and mid-level companies make income within the Market?5. Complete research on the overall development within the Nano Therapy Market that helps you elect the product launch and overhaul growths.

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/1339056-global-nano-therapy-market

Detailed TOC of Nano Therapy Market Research Report-

Nano Therapy Introduction and Market Overview Nano Therapy Market, by Application [Cardiovascular Disease, Cancer Therapy, Diabetes Treatment & Rheumatoid Arthritis]

Nano Therapy Industry Chain Analysis Nano Therapy Market, by Type [, Nanomaterial And Biological Device, Nano Electronic Biosensor, Molecular Nanotechnology & Implantable Cardioverter-Defibrillators]

Industry Manufacture, Consumption, Export, Import by Regions (2013-2018) Industry Value ($) by Region (2013-2018)

Nano Therapy Market Status and SWOT Analysis by Regions

Major Region of Nano Therapy Marketi) Global Nano Therapy Salesii) Global Nano Therapy Revenue & market share Major Companies List Conclusion

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218sales@htfmarketreport.com

Connect with us atLinkedIn|Facebook|Twitter

Original post:
Nano Therapy Market Projected to Show Strong Growth | Key Players: Parvus Therapeutics, Nanoprobes, Nanospectra Biosciences - The Market Journal

Recommendation and review posted by Alexandra Lee Anderson

Nanomedicine: Market by Recent Trends, Development and Growth Forecast by Regions and Applications 20202025 – Instant Tech News

Nanomedicine Market Research Report 2020 This Report Is Comprised with Market Data Derived from Primary as Well As Secondary Research Techniques. The Points Covered in The Report Are Primarily Factors Which Are Considered to Be Market Driving Forces. The Report Aims to Deliver Premium Insights, Quality Data Figures and Information in Relevance with Aspects Such as Market Scope, Market Size, Market Share, Market Segments Including Types of Products and Services, Application Areas, Geographies As Well. It presents the 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Thus, helping the companies to understand the threats and challenges in front of the businesses. Nanomedicine Market is showing steady growth and CAGR is expected to improve during the forecast period.

The Nanomedicine Market Report Incorporates Valuable Differentiating Data Regarding Each of The Market Segments. These Segments Are Studied Further on Various Fronts Including Past Performance, Market Size Contributions, Market Share, Expected Rate of Growth, And More.

The Major Players in the Nanomedicine Market are Profiled in detail in View of Qualities and Share of The Overall Industry.GE HealthcareJohnson & JohnsonMallinckrodt plcMerck & Co. Inc.Nanosphere Inc.Pfizer Inc.Sigma-Tau Pharmaceuticals Inc.Smith & Nephew PLCStryker CorpTeva Pharmaceutical Industries Ltd.UCB (Union chimique belge) S.AKey Businesses Segmentation of Nanomedicine Market

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):Regenerative MedicineIn-vitro & In-vivo DiagnosticsVaccinesDrug Delivery

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):Clinical CardiologyUrologyGeneticsOrthopedicsOphthalmology

In Conclusion, Nanomedicine Market Report Presents the Descriptive Analysis of the Parent Market Based On Elite Players, Present, Past and Futuristic Data Which Will Serve as A Profitable Guide for All the Nanomedicine Market Competitors.

Purchase FULL Report Now! https://www.qurateresearch.com/report/buy/HnM/global-nanomedicine-market/QBI-99S-HnM-655650

Major Players: The report provides company profiling for a decent number of leading players of the global Nanomedicine market. It brings to light their current and future market growth taking into consideration their price, gross margin, revenue, production, areas served, production sites, and other factors.

Industry Overview: The first section of the research study touches on an overview of the global Nanomedicine market, market status and outlook, and product scope. Additionally, it provides highlights of key segments of the global Nanomedicine market, i.e. regional, type, and application segments.

Nanomedicine Market Dynamics: The report shares important information on influence factors, market drivers, challenges, opportunities, and market trends as part of market dynamics.

Regional Market Analysis: It could be divided into two different sections: one for regional production analysis and the other for regional consumption analysis. Here, the analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all regional markets studied in the report.

Global Nanomedicine Market Forecast: Readers are provided with production and revenue forecasts for the global Nanomedicine market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the global Nanomedicine market by type, and consumption forecast for the global Nanomedicine market by application.

Nanomedicine Market Competition: In this section, the report provides information on competitive situation and trends including merger and acquisition and expansion, market shares of top three or five players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Contact Us:Web: http://www.qurateresearch.comE-mail: [emailprotected]Ph: US +13393375221, IN +919881074592

Qurate Business Intelligence delivers unique Market research solutions to its customers and help them to get equipped with refined information and Market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Read the original:
Nanomedicine: Market by Recent Trends, Development and Growth Forecast by Regions and Applications 20202025 - Instant Tech News

Recommendation and review posted by Alexandra Lee Anderson

Sunway University Researchers Recognised with the Vice-Chancellor’s Research Award – QS WOW News

In its aim towards becoming the countrys international education hub, Sunway University is moving forward in its pursuit of excellence not only in academia but also through innovative research.

At the end of last year, four Sunway University researchers were recognised with the Vice-Chancellors Research Award. The recipients were; Associate Professor Dr Yong Min Hooi from the Department of Psychology who received the Special Research Award, Professor Saidur Rahman of the Research Centre for Nano-Materials and Energy Technology with the Award for Achievement in Research, Dr Ayaz Anwar of the Department of Biological Sciences and Dr Hassanudin Mohd Thas Thaker from the Department of Economics and Finance who each received the Award for Achievement in Research for Early Career Researcher.

Associate Professor Dr Yong Min Hoois research focusses on ageing, specifically, executive function and social cognition in older adults. Dr Yong received the Long-Term Research Grant Scheme (LRGS) from the Ministry of Education Malaysia, amounting to RM2.47 million for a 5-year research on Successful ageing: Evidence-based interventions to delay ageing-related decline. This is first single largest grant received in the history of Sunway University. The five-year term from 1 December 2019, scheduled to be completed by 30 November 2024, is categorised under the Aging cluster within Health research cluster and governed under the Sunway Universitys Research Ethics Committee.

Dr Yong previously received various grants from the Newton-Ungku Omar Fund from British Council and the Malaysian Industry-Government Group for High Technology (MIGHT), Arts and Humanities Research Council UK, and Fundamental Research Grant Scheme (FRGS) from Ministry of Higher Education.

Professor Saidur Rahman is Head of the Research Centre for Nano-Materials and Energy Technology. His research focus is in the area of emerging nano-materials, applications in harvesting and storing of solar energy. He has been recognised as a highly cited researcher, listed as the top 1% researchers for most cited documents in his research field of nanofluids for the last 6 years (2014-2019).

Dr Ayaz Anwars current research projects focus on nanomedicine and medicinal chemistry for the development of antimicrobial chemotherapy. His research on silver nanoparticles targeting brain eating amoeba gained international coverage and was featured in the New York Times.

Dr Hassanudin Mohd Thas Thaker research focus in Islamic banking and finance, real estate finance, financial markets, derivatives, and economics has been recognised internationally, earning him the Emerald Literati award in 2016.

Sunway University has 9 research centres and one research group under its roof where research across various fields of study is encouraged.

Go here to see the original:
Sunway University Researchers Recognised with the Vice-Chancellor's Research Award - QS WOW News

Recommendation and review posted by Alexandra Lee Anderson


Page 3«..2345..1020..»